Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.

Sci Rep · 2025 · PMC12816663 · PMID 41444363

Europe PMC DOI

hedged sentence

0.0350

closest p · 0.7× alpha

0.0350

boldest claim

The sentences

showed a trendp = 0.035actually significant

DRGs treated with human bevacizumab + FUS (nDRGs = 12; voxel: 98.2 ± 43.7; diameter: 0.86 ± 0.14 mm) showed a trend to being smaller ( p = 0.035) than those receiving human bevacizumab alone (nDRGs = 24; voxel: 144.8 ± 72.1; diameter: 1.02 ± 0.17 mm).

also in 24,539 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.